This article is going to review the benefits of metformin in prediabetic (PD) patients and the modifications of cardiovascular disease such as coronary artery disease, atherosclerosis, high blood pressure, and cardiovascular events and mortality. This article will highlight the areas of prediabetic care that need improvement. It will discuss the mechanism of action of Metformin and pathophysiology of the effect on the cardiovascular system. With Diabetes Mellitus Type two (DMII) listed as an independent risk factors for cardiovascular disease, front line providers should work towards better detection and management of PD in order to modify the effects on the cardiovascular system.1,2,3 Providing information through this article can improve the knowledge and skill of healthcare providers who are managing PD in their practices. The goal is to encourage better screening for PD patients and initiate more aggressive management of the disease to avoid future development of comorbidities such as cardiovascular disease.
"Metformin Modifies Prediabetic Associated Cardiovascular Disease,"
Lynchburg Journal of Medical Science: Vol. 2
, Article 8.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol2/iss4/8
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.